Buy & Sell ADMA Biologics Inc (ADMA) – ADMA Biologics Inc Price Today
Aura AI Summary
ADMA Biologics (ADMA) trades at $11.26, showing positive momentum with a 1.62% daily gain. The stock presents a complex picture: strong fundamental profitability with a 28.8% net margin and robust ROE of 35.56% contrasts with significant technical overbought signals and a wave of securities fraud investigations. Analyst consensus remains overwhelmingly bullish with an $22.50 price target, representing nearly 100% upside potential, while recent earnings have generally met or exceeded expectations.
The investment case hinges on whether strong operational performance and analyst optimism can overcome mounting legal risks and technical overextension. While fundamentals appear solid with expanding Asceniv demand, the stock faces immediate headwinds from multiple securities investigations alleging channel stuffing, creating substantial uncertainty for shareholders despite Wall Street's positive ratings.
Key Stats
- $2.62BMarket Cap
- HealthSector
- -52.68%3M Drawdown
- $2.61BEnterprise Value
- -Dividend Yield
- 8 daysTypical Hold Time
52W Low: $8.29
26 Mar 2026
52W High: $24.51
28 Apr 2025
ADMA Biologics Inc (ADMA) is currently valued at a market capitalization of $2.62B, with an enterprise value of $2.61B. Over the past 52 weeks, ADMA Biologics Inc has traded between a low of $8.29 and a high of $24.51, highlighting its annual price range. Over the past three months, ADMA Biologics Inc has recorded a drawdown of -52.68%, reflecting recent price volatility. On average, investors hold ADMA Biologics Inc for approximately 8 days, indicating typical investor behavior on the platform.
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Technical Indicators
|
|
|
Overall Summary
Bearish (19)Neutral (5)Bullish (3)
News
People also bought
US Stocks risk is managed by PT PG Berjangka which has a license from the Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by the Jakarta Futures Exchange (JFX) and the Indonesian Clearing House (KBI). Read our product’s Terms and Conditions. View Terms and Conditions